Radiology, Vol 202, 87-95, Copyright © 1997 by Radiological Society of North America

ARTICLES

Breast neoplasms: T2* susceptibility-contrast, first-pass perfusion MR imaging

CK Kuhl, H Bieling, J Gieseke, T Ebel, P Mielcarek, F Far, P Folkers, A Elevelt and HH Schild
Department of Radiology, University of Bonn, Germany.

PURPOSE: To evaluate the differentiation of benign from malignant breast tumors with T2*-weighted perfusion magnetic resonance (MR) imaging (blood volume imaging) versus that with dynamic T1-weighted contrast agent-enhanced MR imaging. MATERIALS AND METHODS: Ten healthy adult volunteers and 18 adult patients with benign or malignant lesions underwent both conventional T1-weighted dynamic contrast-enhanced breast MR imaging and repetitive first-pass, single-section, dynamic T2*-weighted perfusion MR imaging. Images were obtained before, during, and after injection of 20 mL of gadopentetate dimeglumine; peak gadopentetate dimeglumine concentrations were calculated from the maximal signal intensity loss on T2*-weighted images. RESULTS: No perfusion effect was detectable in healthy breast parenchyma. A strong susceptibility-mediated signal intensity loss occurred in malignant breast tumors. No or only minor perfusion effects were seen in fibroadenomas, in spite of their rapid enhancement at T1-weighted dynamic imaging. Perfusion imaging was possible after conventional dynamic contrast-enhanced breast MR imaging. CONCLUSION: T2*-weighted perfusion imaging exploits the susceptibility-mediated signal intensity loss of a first-pass bolus of gadopentetate dimeglumine within the capillary bed. First-pass perfusion imaging of breast lesions is feasible. It is promising in the differentiation of benign from malignant, rapidly enhancing lesions.

This article has been cited by other articles:

				C. K. Kuhl, F. Traber, J. Gieseke, W. Drahanowsky, N. Morakkabati-Spitz, W. Willinek, M. von Falkenhausen, C. Manka, and H. H. Schild Whole-Body High-Field-Strength (3.0-T) MR Imaging in Clinical Practice * Part II. Technical Considerations and Clinical Applications Radiology, April 1, 2008; 247(1): 16 - 35. [Abstract] [Full Text] [PDF]

				C. Kuhl The Current Status of Breast MR Imaging * Part I. Choice of Technique, Image Interpretation, Diagnostic Accuracy, and Transfer to Clinical Practice Radiology, August 1, 2007; 244(2): 356 - 378. [Abstract] [Full Text] [PDF]

				A Jackson Analysis of dynamic contrast enhanced MRI Br. J. Radiol., December 1, 2004; 77(suppl_2): S154 - S166. [Full Text] [PDF]

				W. Huang, P. R. Fisher, K. Dulaimy, L. A. Tudorica, B. O'Hea, and T. M. Button Detection of Breast Malignancy: Diagnostic MR Protocol for Improved Specificity Radiology, August 1, 2004; 232(2): 585 - 591. [Abstract] [Full Text] [PDF]

				A R Padhani MRI for assessing antivascular cancer treatments Br. J. Radiol., December 1, 2003; 76(suppl_1): S60 - S80. [Abstract] [Full Text] [PDF]

				J.-P. Delille, P. J. Slanetz, E. D. Yeh, D. B. Kopans, and L. Garrido Breast Cancer: Regional Blood Flow and Blood Volume Measured with Magnetic Susceptibility-based MR Imaging—Initial Results Radiology, March 21, 2002; (2002) 2232010428. [Abstract] [Full Text]

				K. A. Kvistad, J. Rydland, J. Vainio, H. B. Smethurst, S. Lundgren, H. E. Fjøsne, and O. Haraldseth Breast Lesions: Evaluation with Dynamic Contrast-enhanced T1-weighted MR Imaging and with T2*-weighted First-Pass Perfusion MR Imaging Radiology, August 1, 2000; 216(2): 545 - 553. [Abstract] [Full Text]

				J.-P. Delille, P. J. Slanetz, E. D. Yeh, D. B. Kopans, and L. Garrido Breast Cancer: Regional Blood Flow and Blood Volume Measured with Magnetic Susceptibility-based MR Imaging—Initial Results Radiology, May 1, 2002; 223(2): 558 - 565. [Abstract] [Full Text] [PDF]